Does the media refer more to RVPH or KYNB?

In the previous week, Kyntra Bio had 1 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 2 mentions for Kyntra Bio and 1 mentions for Reviva Pharmaceuticals. Kyntra Bio's average media sentiment score of 0.93 beat Reviva Pharmaceuticals' score of 0.00 indicating that Kyntra Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Reviva Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TVRD or RVPH more profitable?

Tvardi Therapeutics' return on equity of -64.17% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -64.17% -43.90% Reviva Pharmaceuticals N/A -391.58% -119.08%

Does the media prefer TVRD or RVPH?

In the previous week, Tvardi Therapeutics had 9 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 10 mentions for Tvardi Therapeutics and 1 mentions for Reviva Pharmaceuticals. Tvardi Therapeutics' average media sentiment score of 0.61 beat Reviva Pharmaceuticals' score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Reviva Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, RVPH or PLRZ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Reviva Pharmaceuticals N/A N/A -$19.86M -$4.06 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is RVPH or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Reviva Pharmaceuticals N/A -391.58% -119.08% Polyrizon N/A N/A N/A

Does the media favor RVPH or PLRZ?

In the previous week, Polyrizon had 1 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 2 mentions for Polyrizon and 1 mentions for Reviva Pharmaceuticals. Polyrizon's average media sentiment score of 1.39 beat Reviva Pharmaceuticals' score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Reviva Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Polyrizon 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DARE or RVPH more profitable?

Dare Bioscience's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% Reviva Pharmaceuticals N/A -391.58% -119.08%

Does the media favor DARE or RVPH?

In the previous week, Dare Bioscience had 1 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 2 mentions for Dare Bioscience and 1 mentions for Reviva Pharmaceuticals. Dare Bioscience's average media sentiment score of 0.94 beat Reviva Pharmaceuticals' score of 0.00 indicating that Dare Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Reviva Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LSTA or RVPH more profitable?

Lisata Therapeutics' return on equity of -103.54% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -103.54% -83.08% Reviva Pharmaceuticals N/A -391.58% -119.08%

Reviva Pharmaceuticals (RVPH) Competitors

$0.55 -0.04 (-7.08%)

As of 07/14/2026 03:51 PM Eastern

Compare

RVPH vs. KYNB, TVRD, PLRZ, DARE, and LSTA

Should you buy Reviva Pharmaceuticals stock or one of its competitors? MarketBeat compares Reviva Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Reviva Pharmaceuticals include Kyntra Bio (KYNB), Tvardi Therapeutics (TVRD), Polyrizon (PLRZ), Dare Bioscience (DARE), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical products" industry.

How does Reviva Pharmaceuticals compare to Kyntra Bio?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 8.9% of Reviva Pharmaceuticals shares are held by company insiders. Comparatively, 4.2% of Kyntra Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Kyntra Bio has a net margin of 2,199.13% compared to Reviva Pharmaceuticals' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
Kyntra Bio	2,199.13%	N/A	-36.71%

Reviva Pharmaceuticals has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Reviva Pharmaceuticals presently has a consensus target price of $66.67, suggesting a potential upside of 11,999.21%. Kyntra Bio has a consensus target price of $32.50, suggesting a potential upside of 343.99%. Given Reviva Pharmaceuticals' higher probable upside, equities research analysts clearly believe Reviva Pharmaceuticals is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Kyntra Bio has higher revenue and earnings than Reviva Pharmaceuticals. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A
Kyntra Bio	$6.44M	4.60	$183.45M	$40.46	0.18

In the previous week, Kyntra Bio had 1 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 2 mentions for Kyntra Bio and 1 mentions for Reviva Pharmaceuticals. Kyntra Bio's average media sentiment score of 0.93 beat Reviva Pharmaceuticals' score of 0.00 indicating that Kyntra Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Reviva Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kyntra Bio beats Reviva Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Tvardi Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Tvardi Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

Tvardi Therapeutics currently has a consensus target price of $19.67, suggesting a potential upside of 534.41%. Reviva Pharmaceuticals has a consensus target price of $66.67, suggesting a potential upside of 11,999.21%. Given Reviva Pharmaceuticals' higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Tvardi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Tvardi Therapeutics had 9 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 10 mentions for Tvardi Therapeutics and 1 mentions for Reviva Pharmaceuticals. Tvardi Therapeutics' average media sentiment score of 0.61 beat Reviva Pharmaceuticals' score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Reviva Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tvardi Therapeutics has higher revenue and earnings than Reviva Pharmaceuticals. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	4.07	-$18.21M	-$3.10	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by company insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tvardi Therapeutics' return on equity of -64.17% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-64.17%	-43.90%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Summary

Tvardi Therapeutics beats Reviva Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Polyrizon?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Polyrizon's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
Polyrizon	N/A	N/A	N/A

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 8.9% of Reviva Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Reviva Pharmaceuticals has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Polyrizon has a beta of -1.59, suggesting that its share price is 259% less volatile than the broader market.

In the previous week, Polyrizon had 1 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 2 mentions for Polyrizon and 1 mentions for Reviva Pharmaceuticals. Polyrizon's average media sentiment score of 1.39 beat Reviva Pharmaceuticals' score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Reviva Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Polyrizon	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Reviva Pharmaceuticals currently has a consensus price target of $66.67, suggesting a potential upside of 11,999.21%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Reviva Pharmaceuticals is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Summary

Reviva Pharmaceuticals beats Polyrizon on 6 of the 11 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Dare Bioscience has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

In the previous week, Dare Bioscience had 1 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 2 mentions for Dare Bioscience and 1 mentions for Reviva Pharmaceuticals. Dare Bioscience's average media sentiment score of 0.94 beat Reviva Pharmaceuticals' score of 0.00 indicating that Dare Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Reviva Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dare Bioscience presently has a consensus price target of $10.00, suggesting a potential upside of 383.09%. Reviva Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 11,999.21%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Dare Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Dare Bioscience has higher revenue and earnings than Reviva Pharmaceuticals. Dare Bioscience is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.16M	26.80	-$13.40M	-$0.95	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A

Dare Bioscience's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Dare Bioscience beats Reviva Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Lisata Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lisata Therapeutics has higher revenue and earnings than Reviva Pharmaceuticals. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	198.81	-$16.59M	-$1.86	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A

In the previous week, Lisata Therapeutics and Lisata Therapeutics both had 1 articles in the media. Lisata Therapeutics' average media sentiment score of 1.87 beat Reviva Pharmaceuticals' score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lisata Therapeutics	Very Positive
Reviva Pharmaceuticals	Neutral

Lisata Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

Lisata Therapeutics' return on equity of -103.54% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Lisata Therapeutics presently has a consensus price target of $15.00, suggesting a potential upside of 304.31%. Reviva Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 11,999.21%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Lisata Therapeutics beats Reviva Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Reviva Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVPH vs. The Competition

Export

Metric	Reviva Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.22M	$3.02B	$6.86B	$12.44B
Dividend Yield	N/A	2.08%	2.68%	8.42%
P/E Ratio	-0.14	18.77	26.96	24.38
Price / Sales	N/A	344.35	521.19	91.92
Price / Cash	N/A	56.83	48.59	59.36
Price / Book	0.37	4.20	10.95	6.33
Net Income	-$19.86M	$65.13M	$3.59B	$331.02M
7 Day Performance	3.96%	-2.63%	-1.49%	-0.33%
1 Month Performance	-21.29%	2.14%	2.75%	-1.29%
1 Year Performance	-92.93%	23.26%	28.51%	21.30%

Reviva Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVPH Reviva Pharmaceuticals	1.997 of 5 stars	$0.55 -7.1%	$66.67 +11,999.2%	-93.6%	$7.22M	N/A	N/A	5	News Coverage
KYNB Kyntra Bio	3.5574 of 5 stars	$7.34 -3.5%	$32.50 +342.8%	N/A	$30.79M	$6.44M	0.18	570
TVRD Tvardi Therapeutics	2.8094 of 5 stars	$3.31 +0.9%	$19.67 +494.2%	-89.6%	$30.77M	$7.14M	N/A	80	Gap Down
PLRZ Polyrizon	0.8374 of 5 stars	$13.86 -5.4%	N/A	+236.2%	$30.53M	N/A	N/A	N/A	Positive News Analyst Upgrade Gap Up
DARE Dare Bioscience	2.4589 of 5 stars	$2.09 +3.5%	$10.00 +378.5%	-33.0%	$30.26M	$1.03M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RVPH) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Reviva Pharmaceuticals (RVPH) Competitors

RVPH vs. KYNB, TVRD, PLRZ, DARE, and LSTA

How does Reviva Pharmaceuticals compare to Kyntra Bio?

Summary

How does Reviva Pharmaceuticals compare to Tvardi Therapeutics?

Summary

How does Reviva Pharmaceuticals compare to Polyrizon?

Summary

How does Reviva Pharmaceuticals compare to Dare Bioscience?

Summary

How does Reviva Pharmaceuticals compare to Lisata Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH vs. The Competition

Reviva Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Reviva Pharmaceuticals (RVPH) Competitors

RVPH vs. KYNB, TVRD, PLRZ, DARE, and LSTA

How does Reviva Pharmaceuticals compare to Kyntra Bio?

Do insiders & institutionals believe in RVPH or KYNB?

Is RVPH or KYNB more profitable?

Which has more risk & volatility, RVPH or KYNB?

Do analysts prefer RVPH or KYNB?

Which has better earnings & valuation, RVPH or KYNB?

Does the media refer more to RVPH or KYNB?

Summary

How does Reviva Pharmaceuticals compare to Tvardi Therapeutics?

Which has more volatility and risk, TVRD or RVPH?

Do analysts rate TVRD or RVPH?

Does the media prefer TVRD or RVPH?

Which has stronger earnings and valuation, TVRD or RVPH?

Do institutionals & insiders believe in TVRD or RVPH?

Is TVRD or RVPH more profitable?

Summary

How does Reviva Pharmaceuticals compare to Polyrizon?

Is RVPH or PLRZ more profitable?

Do institutionals & insiders hold more shares of RVPH or PLRZ?

Which has more risk & volatility, RVPH or PLRZ?

Does the media favor RVPH or PLRZ?

Do analysts prefer RVPH or PLRZ?

Which has preferable valuation & earnings, RVPH or PLRZ?

Summary

How does Reviva Pharmaceuticals compare to Dare Bioscience?

Which has more volatility & risk, DARE or RVPH?

Does the media favor DARE or RVPH?

Do analysts rate DARE or RVPH?

Which has better valuation & earnings, DARE or RVPH?

Is DARE or RVPH more profitable?

Do insiders and institutionals have more ownership in DARE or RVPH?

Summary

How does Reviva Pharmaceuticals compare to Lisata Therapeutics?

Do institutionals and insiders hold more shares of LSTA or RVPH?

Which has better valuation & earnings, LSTA or RVPH?

Does the media refer more to LSTA or RVPH?

Which has more volatility and risk, LSTA or RVPH?

Is LSTA or RVPH more profitable?

Do analysts prefer LSTA or RVPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH vs. The Competition

Reviva Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools